MAP4K2

Across TCGA pan-cancer cohorts, MAP4K2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAP4K2 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAP4K2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP4K2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where MAP4K2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.845	0.359	<.001	57	view →
LUAD	DFS	Median	II,III,IV	0.836	0.306	.009	10	view →
PDAC	OS	Median	IV	0.405	0.828	.038	3	view →
UCEC	OS	Median	All	0.919	0.981	.048	2	view →
LSCC	OS	Median	All	0.800	1.000	.044	2	view →
HNSC	OS	Median	III,IV	0.828	0.579	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAP4K2–CCRCC (DFS)

Open the CCRCC breakdown →